Welcome to our dedicated page for Organovo Holding news (Ticker: ONVO), a resource for investors and traders seeking the latest updates and insights on Organovo Holding stock.
Overview of Organovo Holding (ONVO)
Organovo Holding (ONVO) is a clinical stage biotechnology company that excels in designing and creating functional, three-dimensional human tissues using advanced 3D tissue engineering techniques. As a pioneer in the field of drug discovery and medical research, Organovo leverages proprietary technology to fabricate human tissue models that closely mimic native tissue architecture, function, and disease pathology. This innovative approach not only enables accurate biological disease models but also supports faster, more cost-effective therapeutic development.
Core Business and Technological Innovation
At the heart of Organovo’s operations is its breakthrough technology for fabricating functional 3D human tissues. The company collaborates with pharmaceutical companies and academic institutions, employing its engineered tissues to simulate complex human diseases. This technology facilitates a new dimension of preclinical testing, allowing researchers to study disease processes in an environment that closely resembles in vivo conditions. Organovo's technology is especially significant in accelerating drug development, as realistic tissue models can reveal critical insights into drug efficacy and safety early in the research cycle.
Scientific and Clinical Research Applications
Organovo’s expertise extends into the realm of clinical research where its preclinical data supports the development of novel drug candidates. One of its notable endeavors is the investigation of FXR314, a drug candidate for inflammatory bowel disease, including ulcerative colitis. By utilizing its 3D human tissue models, the company is able to demonstrate clinical promise, further emphasizing its role in translating laboratory research into potential therapeutic applications for complex diseases. This versatile platform not only aids in understanding gastrointestinal and liver diseases but has implications in oncology and metabolic liver conditions as well.
Collaborations and Industry Recognition
The company’s approach to tissue engineering has garnered attention from diverse sectors. By establishing strategic partnerships with leading academic and pharmaceutical entities, Organovo has positioned itself as an essential collaborator in the development of robust disease models. Its scientific advancements have been validated through multiple peer-reviewed publications and featured in reputable media outlets. Such recognition reinforces the reliability and innovative nature of its technology, contributing to a solid reputation within the biotechnology community.
Competitive Landscape and Market Positioning
Operating within the competitive biotechnology and tissue engineering landscape, Organovo differentiates itself through its unique capability to recreate human physiological conditions with high fidelity. While the industry is marked by rapid technological advancements and intense research activity, Organovo’s focus on structurally and functionally relevant tissue models provides a compelling value proposition. The company’s collaborations with research institutions and its continued pursuit of functional tissue applications have established it as a key player in the niche market of advanced therapeutic research tools.
Applications in Drug Discovery and Medical Research
Organovo’s 3D human tissue technology is explicitly designed to serve two critical areas: medical research and drug discovery. In the context of drug development, the platform enables the creation of disease-specific models, thereby assisting researchers in evaluating drug responses in environments that accurately reflect human biology. This not only streamlines the process of determining therapeutic viability but also assists in identifying potential adverse reactions early in the development phase. By bridging the gap between traditional cell culture methods and animal models, Organovo’s approach contributes significantly to reducing the translational gap in modern pharmacological research.
Scientific Integrity and Long-Term Relevance
The expertise behind Organovo is underpinned by rigorous scientific research and continual innovation. Its work is well-documented in scientific literature and has been the subject of numerous case studies, which further substantiate the effectiveness of its engineered tissues. The company maintains a neutral, research-driven perspective, offering comprehensive insights into its methodologies without resorting to promotional or speculative language. This commitment to scientific integrity ensures that the information remains relevant and accurate over the long term.
Conclusion
In summary, Organovo Holding stands as a noteworthy contributor to the fields of biotechnology and medical research. Through its cutting-edge 3D tissue engineering technology, the company addresses fundamental challenges in drug discovery and therapeutic development. Its well-established partnerships, robust scientific foundation, and innovative clinical research applications underscore its importance within a rapidly evolving industry. For investors and researchers seeking detailed, unbiased insights into the company’s operations and business model, Organovo provides a compelling case study in the practical application of advanced tissue engineering for medical advancements.
Organovo Holdings (NASDAQ:ONVO), a clinical stage biotechnology company focused on inflammatory bowel disease (IBD), provided a business update following the sale of its FXR Program to Lilly (NYSE:LLY). The company has received upfront payments and expects future milestone payments from this deal.
The company anticipates reduced expenditures in the coming year due to the elimination of FXR314-related costs. With current capital and excluding potential milestone payments, Organovo expects to maintain operations through FY2026. The company plans to report FY2025 financials around June 6-10, 2025.
Organovo utilizes 3D human cellular models of Crohn's disease and ulcerative colitis to evaluate therapeutic opportunities. In 2024, FXR314 showed promising results in IBD treatment, demonstrating improved epithelial barrier function and fibrotic activity in ulcerative colitis, as well as synergistic benefits when combined with JAK inhibitors. The drug also showed potential in treating liver fibrosis in Phase 2 MASH trials.
Organovo Holdings (NASDAQ:ONVO) has successfully completed the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) on March 25, 2025. The transaction includes an upfront payment to Organovo, with additional milestone payments tied to FXR314's regulatory and commercial achievements.
As part of the deal, Lilly acquires worldwide development rights and all commercial and intellectual property rights to Organovo's FXR program. Lilly will assume responsibility for all future clinical development of the program.
Organovo Holdings (ONVO) has announced a 1-for-12 reverse stock split effective March 20, 2025, at 5:00 p.m. Eastern Time. The stock will begin trading on a split-adjusted basis on March 21, 2025, maintaining its Nasdaq symbol 'ONVO' with a new CUSIP number.
The split will reduce outstanding shares from approximately 21.4 million to 1.8 million, with no change to the par value of $0.001 per share or the authorized number of shares. Stockholders with fractional shares will receive cash payments based on the closing price on March 19, 2025.
This strategic move aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The split ratio was approved by the board on March 6, 2025, following stockholder authorization granted at the November 20, 2024 annual meeting.
Organovo Holdings (ONVO), a clinical stage biotechnology company focused on inflammatory bowel disease (IBD) treatments, has announced the issuance of 2,967,144 additional shares of common stock through warrant exercises and at-the-market sales.
The share issuance, registered under statements effective May 8, 2024, is expected to generate gross proceeds of approximately $2.3 million, before deducting fees and commissions. Following this issuance, Organovo's total outstanding common stock has reached 20,421,617 shares.
Organovo Holdings (Nasdaq: ONVO) has announced that Eli Lilly and Company (NYSE: LLY) will acquire its FXR program, including lead asset FXR314. This represents a significant milestone for Organovo's efforts to advance medicines for inflammatory bowel disease (IBD) using insights from their proprietary 3D human tissue models.
Under the transaction terms, Organovo will receive an upfront payment and additional milestone payments as FXR314 achieves key regulatory and commercial targets. Lilly is acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development.
Keith Murphy, Executive Chairman of Organovo, expressed excitement about delivering FXR314 and the FXR program to Lilly for Phase 2 and further development, citing Lilly's world-class development excellence and dedication to patients as providing an excellent pathway for FXR314's success.
Organovo Holdings (NASDAQ:ONVO) has appointed Norman Staskey as Chief Financial Officer. Staskey, who has worked at Danforth Advisors since 2021, brings over 25 years of experience in capital markets and M&A transactions, including his role as Managing Director in EY's national transactions practice.
The company recently presented Phase 2 results for its lead drug FXR314 in MASH treatment, showing statistically significant reduction in liver fat content with lower pruritus rates compared to other FXR agonists. The study involved 214 patients. Additionally, 2024 data demonstrated FXR314's potential in IBD treatment, showing improved epithelial barrier function and fibrotic activity in ulcerative colitis models, as well as synergistic benefits when combined with JAK inhibitors.
Organovo anticipates a Phase 2 study to demonstrate FXR314's effectiveness in moderate to severe ulcerative colitis, with potential development as both monotherapy and combination therapy.
Organovo Holdings (NASDAQ:ONVO) presented Phase 2 clinical trial results for FXR314 at The Liver Meeting. The study involved 214 MASH patients randomized to receive 3mg, 6mg FXR314, or placebo. The drug demonstrated statistically significant liver fat reduction from baseline: 22.8% (3mg) and 17.5% (6mg) versus 6.1% placebo. Notably, >30% MRI-PDFF reduction was achieved in 29.2% (3mg) and 32.2% (6mg) of subjects compared to 9.5% with placebo. FXR314 showed improved safety profile with lower pruritus rates (2.8-4.2%) compared to other FXR agonists, and minimal LDL-C level changes.
Organovo Holdings (Nasdaq: ONVO) announces that its lead clinical stage drug, FXR314, will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, scheduled for November 17, 2024, will be delivered by Dr. Eric Lawitz of the Texas Liver Institute and will discuss findings from the FXR314 Phase 2 MASH study. The presentation will cover pharmacokinetics, safety, and efficacy of this novel non-bile acid FXR agonist in patients with metabolic dysfunction-associated steatohepatitis.
Organovo Holdings (Nasdaq: ONVO) presented its outlook and plans at the Jones Trading Healthcare Conference, focusing on FXR314, its treatment for inflammatory bowel disease (IBD). Executive Chairman Keith Murphy highlighted the strong preclinical and human rationale for FXR314 in Phase 2a ulcerative colitis trials. The company aims to demonstrate FXR314's activity matching results from predictive animal models and 3D human models of ulcerative colitis and Crohn's disease. Murphy emphasized the importance of swift trial completion for investors and patients, noting the strong M&A activity in IBD, referencing Lilly's $3.2B acquisition of Morphic following positive Phase 2a results. The presentation webcast is available for viewing on the Jones Trading website.
Organovo Holdings (Nasdaq: ONVO) presented promising data at Digestive Disease Week (DDW2024) in Washington, D.C., showcasing the potential of FXR314 for treating inflammatory bowel disease (IBD). The study highlights the benefits of combining FXR314, a non-steroidal, non-bile acid FXR agonist, with tofacitinib, a JAK inhibitor. Results showed improvements in intestinal barrier function, inflammation, and fibrosis in 3D and preclinical IBD models. Both compounds, when used at optimal and sub-efficacious concentrations, demonstrated enhanced therapeutic effects. FXR314 alone also showed similar efficacy to approved therapies. These findings support the potential of FXR314 for monotherapy and combination therapy in future clinical studies.
FAQ
What is the current stock price of Organovo Holding (ONVO)?
What is the market cap of Organovo Holding (ONVO)?
What is Organovo Holding's primary focus?
How does Organovo generate revenue?
What distinguishes Organovo's 3D tissue engineering technology?
What is FXR314 and why is it significant?
Who are Organovo's typical partners?
How has Organovo been recognized in the media?
What challenges does Organovo face?
How does Organovo contribute to the drug discovery process?
